Contact
searchSearch
HMP Global
Login

June 2019

Column

Editor's Page
Predictive Methodologies to Better Manage Costs of Innovative Therapies
06/18/2019
Winston Wong, PharmD
Novel innovations in cell and gene therapies mark a new era in medicine whereby durable remission, and potentially cures, are within reach for several diseases. These advancements are clearly beneficial and have been...
Novel innovations in cell and gene therapies mark a new era in medicine whereby durable remission, and potentially cures, are within reach for several diseases. These advancements are clearly beneficial and have been...
Novel...
06/18/2019
Journal of Clinical Pathways
Editorial
The Real-Life Patient Impact of Pharmacy Benefit Managers
06/18/2019
Nicolas Ferreyros
The Centers for Medicare & Medicaid Services (CMS) recently released a final rule for Medicare Part D that codified its decision to allow Medicare Advantage plans to use step therapy, or “fail first,” for new...
The Centers for Medicare & Medicaid Services (CMS) recently released a final rule for Medicare Part D that codified its decision to allow Medicare Advantage plans to use step therapy, or “fail first,” for new...
The...
06/18/2019
Journal of Clinical Pathways
Pharma Insights
Evolution of Hub Services
06/18/2019
Chrysanthe Peteros, MPH; Larry Blandford, PharmD; Chris Dillon, BS 
What began as patient call centers for select complex medicines has expanded to a full suite of support services, ranging from financial assistance to patient education: so-called hub services have become ubiquitous...
What began as patient call centers for select complex medicines has expanded to a full suite of support services, ranging from financial assistance to patient education: so-called hub services have become ubiquitous...
What...
06/18/2019
Journal of Clinical Pathways
Business of Pathways
Cell and Gene Therapies: Paying It Forward and Adjusting Payment Systems for the Age of Cures
06/18/2019
Ira Klein, MD, MBA, FACP; Sean McElligott, MS
Cell and gene therapies represent the next frontier of pharmaceutical development, holding the promise of delivering potentially curative therapies for diseases that have limited treatment options. However, these...
Cell and gene therapies represent the next frontier of pharmaceutical development, holding the promise of delivering potentially curative therapies for diseases that have limited treatment options. However, these...
Cell...
06/18/2019
Journal of Clinical Pathways

News

Conference Coverage
American Society of Clinical Oncology 2019 Annual Meeting
06/18/2019
The American Society of Clinical Oncology (ASCO) is the leading professional organization for physicians and oncology professionals caring for people with cancer. Through its multidisciplinary network of almost...
The American Society of Clinical Oncology (ASCO) is the leading professional organization for physicians and oncology professionals caring for people with cancer. Through its multidisciplinary network of almost...
The...
06/18/2019
Journal of Clinical Pathways

Department

Clinical Pathways Forum
Oncology Clinical Pathways: The Yale Experience
06/18/2019
Mishellene McKinney, MHA, RN, OCN
Founded in 2016, the Clinical Pathways Forum is a community of pathways professionals­—now totaling over 12 institutions from across the United States and Canada—who are utilizing clinical pathways in their practices...
Founded in 2016, the Clinical Pathways Forum is a community of pathways professionals­—now totaling over 12 institutions from across the United States and Canada—who are utilizing clinical pathways in their practices...
...
06/18/2019
Journal of Clinical Pathways

Feature

Research Reports
Drug Costs vs Probability of Survival in Lung Cancer: Impact of Dosage, Duration, and Immune Checkpoint Inhibitor Combinations
06/18/2019
Helmy M. Guirgis, MD, PhD
Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-small cell lung cancer (amNSCLC). There is an unmet need...
Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-small cell lung cancer (amNSCLC). There is an unmet need...
...
06/18/2019
Journal of Clinical Pathways
Perspectives
On the Horizon for Value-Based Oncology Care: Predictive Analytics, Novel Therapy Pricing Pressures, New Payment Models, and a Rise in Complex Data Sources
06/18/2019
Jennifer Webster, MS; Charles Saunders, MD
Abstract: January 2019 represented another major inflection point for the Oncology Care Model (OCM), marking the halfway point of the 5-year program. Overall, while OCM participants have expressed concerns about...
Abstract: January 2019 represented another major inflection point for the Oncology Care Model (OCM), marking the halfway point of the 5-year program. Overall, while OCM participants have expressed concerns about...
...
06/18/2019
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Volume 5

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use